menu search

High-sensitivity troponin assays may stratify risk in chronic cad

An exploratory analysis suggests an elevated troponin level may identify patients who would benefit from revas...

August 1, 2023, 4:03 pm

More angina relief with complete revascularization in stable cad: ischemia

Complete revascularization with PCI results in better health status for patients with multivessel, stab...

July 18, 2023, 8:59 pm

Amarin announces new reduce-it® data at acc.23/wcc showing benefit of vascepa®/vazkepa® (icosapent ethyl) in high-risk patients with a recent acute coronary syndrome event

–Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS With...

March 5, 2023, 3:21 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm

Landmark clear outcomes study demonstrates nexletol® (bempedoic acid) tablet is the only ldl-c lowering therapy since statins to reduce hard ischemic events in a broad population of both primary preve

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEX...

March 4, 2023, 3:30 pm


Search within

Pages Search Results: